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Summary
 
Induction of neonatal T cell tolerance to soluble antigens requires the use of incomplete
Freund’s adjuvant (IFA). The side effects that could be associated with IFA and the ill-defined
mechanism underlying neonatal tolerance are setbacks for this otherwise attractive strategy for
prevention of T cell–mediated autoimmune diseases. Presumably, IFA contributes a slow anti-
gen release and induction of cytokines influential in T cell differentiation. Immunoglobulins
(Igs) have long half-lives and could induce cytokine secretion by binding to Fc receptors on
target cells. Our hypothesis was that peptide delivery by Igs may circumvent the use of IFA and
induce neonatal tolerance that could confer resistance to autoimmunity. To address this issue
we used the proteolipid protein (PLP) sequence 139–151 (hereafter referred to as PLP1),
which is encephalitogenic and induces experimental autoimmune encephalomyelitis (EAE) in
SJL/J mice. PLP1 was expressed on an Ig, and the resulting Ig–PLP1 chimera when injected in
saline into newborn mice confers resistance to EAE induction later in life. Mice injected with
Ig–PLP1 at birth and challenged as adults with PLP1 developed T cell proliferation in the
lymph node but not in the spleen, whereas control mice injected with Ig–W, the parental Ig
not including PLP1, developed T cell responses in both lymphoid organs. The lymph node T
cells from Ig–PLP1 recipient mice were deviated and produced interleukin (IL)-4 instead of
IL-2, whereas the spleen cells, although nonproliferative, produced IL-2 but not interferon
(IFN)-
 
g
 
. Exogenous IFN-
 
g
 
, as well as IL-12, restored splenic proliferation in an antigen spe-
cific manner. IL-12–rescued T cells continued to secrete IL-2 and regained the ability to pro-
duce IFN-
 
g
 
. In vivo, administration of anti–IL-4 antibody or IL-12 restored disease severity.
Therefore, adjuvant-free induced neonatal tolerance prevents autoimmunity by an organ-spe-
cific regulation of T cells that involves both immune deviation and a new form of cytokine-
dependent T cell anergy.
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early half a century ago, it was shown that mice in-
jected at birth with splenic cells from an allogeneic
donor were later able to accept grafts from the same donor
(1). Ever since, the neonatal period has been considered a
critical window during which an initial contact with anti-
gen will instruct the immune system to ignore such an anti-
gen and not respond to it during a subsequent encounter.
Soon after the discovery that T cells recognize rather
short antigenic fragments, tolerization regimens using pep-
tides in IFA were defined that induced clonal unrespon-
siveness and mediated neonatal tolerance (2, 3). However,
recent developments indicated that antigen injection dur-
ing the neonatal stage can immunize rather than suppress
(4, 5). In allogeneic systems it was discovered that graft ac-
ceptance by neonatally tolerized animals was due to the de-
velopment of functionally deviated T cells producing Th2-
type cytokines instead of the usual Th1 cytokines produced
by T cells of nontolerized mice (6, 7). These Th2 cells are
unable to support development of the cytolytic T lympho-
cytes required for graft rejection (8). Similarly, neonatal in-
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jection of a self-peptide in IFA, which protected mice from
autoimmune disease induction, was found to operate through
clonal unresponsiveness in the lymph nodes accompanied
by induction of deviated Th2 cells in the spleen (9). The
notion that neonatal injection of antigen can immunize is
now well accepted, and evidence has accumulated indicat-
ing that factors such as the type of APCs (5, 10), the ad-
juvant into which the antigen is emulsified (9), the dose of
antigen (11), and the availability of antigen in vivo (12)
could engender various outcomes ranging from inactiva-
tion of T cells to the priming of an immune response.
Therefore, in the face of this susceptibility to regulation, it
is important to further investigate the outcome of neonatal
antigen injection, particularly to self-antigens, since neona-
tal tolerance could provide a potential strategy for preven-
tion of autoimmunity.
IFA, which has been required for tolerance induction by
soluble proteins and peptides, may exert adjuvanticity by
contributing a slow release of antigen and inducing cyto-
kine production by APCs (13). However, the use of IFA
may generate side effects and trigger oil-induced arthritis
(14).
Igs are autologous molecules permissive for peptide ex-
pression and can function as a delivery system for T cell
epitopes (15–18). Internalization of Igs into APCs via FcRs
grants the incorporated peptide access to newly synthesized
MHC class II molecules, leading to efficient peptide pre-
sentation and T cell activation (19). For instance, when
the proteolipid protein (PLP)
 
1
 
 139–151 peptide sequence
(hereafter referred to PLP1) was expressed on an Ig mole-
cule, the peptide’s presentation was increased by 100-fold
(20). Furthermore, the Ig–PLP1 chimera was a potent in-
ducer of PLP1-specific T cell responses both in the spleen
and lymph nodes (20, 21). Since Igs are long-lived mole-
cules in vivo, presentation could persist for a long period of
time. In addition by binding FcR on APCs, Igs can trigger
production of cytokines (22, 23). These functions may pro-
vide the Ig delivery system with adjuvant-like properties
that could circumvent the use of IFA for tolerance induc-
tion and prevention of autoimmunity. Here, we report
that Ig–PLP1 injected into newborn mice in saline confers
resistance to experimental autoimmune encephalomyelitis
(EAE) induction by a novel mechanism defined by IL-4
driven lymph node deviation and an unusual IFN-
 
g
 
–medi-
ated splenic proliferative unresponsiveness.
 
Materials and Methods
 
Mice.
 
6–8-wk-old SJL/J mice (H-2
 
s
 
) were purchased from
Harlan Sprague Dawley (Frederick, MD) and maintained in our
animal facility for the duration of experiments. For the generation
of newborn mice, breeding sets of one adult male and three fe-
males, were caged together, and when pregnancy was visible the
females were separated and caged individually. Offspring were
weaned when they reached 3 wk of age. All experimental proce-
dures were carried out according to the guidelines of the institu-
tional animal care committee.
 
Peptides.
 
All peptides used in these studies were purchased
from Research Genetics, Inc. (Huntsville, AL) and purified by
HPLC to 
 
.
 
90% purity. PLP1 peptide (HSLGKWLGHPDKF)
encompasses an encephalitogenic sequence corresponding to
amino acid residues 139–151 of PLP (24, 25). PLP1 peptide is
presented to T cells in association with I-A
 
s
 
 MHC class II mole-
cules. PLP2 peptide (NTWTTCQSIAFPSK) encompasses an en-
cephalitogenic sequence corresponding to amino acid residues
178–191 of PLP (26). This peptide is also presented by I-A
 
s
 
MHC class II molecules and induces EAE in SJL/J mice.
 
Ig–PLP Chimeras. 
 
Expression of PLP1 peptide on Ig–PLP1
has been described previously (20). Ig–W, the parental Ig not en-
compassing PLP1 peptide, has been described elsewhere (27).
The genes used to construct these chimeras are those coding for
the light and heavy chains of the anti-arsonate antibody, 91A3,
and the procedures for deletion of the heavy chain CDR3 region
and replacement with nucleotide sequences coding for PLP1 are
similar to those described for the generation of Ig–NP (27). Both
Ig–W and Ig–PLP1 are from IgG2b 
 
k
 
 isotypes, and Ig–PLP1 dif-
fers from Ig–W only by encompassing PLP1 peptide. Both chi-
meras were expressed in the non–Ig-secreting myeloma B cell
line SP2/0 (20). Large scale cultures of transfectants were carried
out in DMEM media containing 10% iron-enriched calf serum
(Intergen, Purchase, NY). The Ig chimeras were purified from
culture supernatant on columns made of rat anti–mouse 
 
k 
 
chain
coupled to CNBr-activated Sepharose 4B (Amersham Pharmacia
Biotech, Piscataway, NJ). To avoid cross contamination separate
columns were used to purify the chimeras.
 
Neonatal Injections and Adult Immunizations.
 
Neonatal injec-
tions of Ig chimeras were done intraperitoneally in 50–100 
 
m
 
l sa-
line. When the mice reached 7 wk of age they were subjected to
immunization with peptide in CFA or to EAE induction. Immu-
nization of adult mice with peptide in CFA was carried out sub-
cutaneously in the foot pads and at the base of the limbs and tail.
The peptide was emulsified in a 200 
 
m
 
l PBS/CFA (vol/vol) mix-
ture. 10 d later the mice were killed by cervical dislocation, and
the spleens and lymph nodes (axillary, inguinal, popliteal, and sa-
cral) were removed for analysis of proliferative and cytokine re-
sponses.
 
Induction of EAE.
 
EAE was induced by subcutaneous injec-
tion in the foot pads and at the base of the limbs with a 200 
 
m
 
l
IFA/PBS (vol/vol) solution containing 100 
 
m
 
g free PLP1 peptide
and 200 
 
m
 
g 
 
Mycobacterium
 
 
 
tuberculosis 
 
H37Ra. 6 h later 5 
 
3 
 
10
 
9
 
inactivated 
 
Bordetella pertussis
 
 were given intravenously.
 
 
 
After
48 h, another 5 
 
3 
 
10
 
9
 
 inactivated 
 
B
 
.
 
 pertussis 
 
were given to the
mice. Mice were scored daily for clinical signs as follows: 0, no
clinical signs; 1, loss of tail tone; 2, hindlimb weakness; 3, hind-
limb paralysis; 4, forelimb paralysis; and 5, moribund or death.
 
Assay of Neonatal Splenic and Thymic Cells for Ig–PLP1 Presenta-
tion.
 
Newborn mice were injected intraperitoneally with 100
 
m
 
g Ig–PLP1 or Ig–W in 100 
 
m
 
l saline. 2 d later the spleen and
thymus were removed, and single cell suspensions were prepared,
irradiated (3000 rads), and assayed for stimulation of the PLP1-
specific T cell hybridoma 4E3 (28) without addition of exoge-
nous peptide. In brief, graded numbers of splenic or thymic cells
were incubated with 5 
 
3 
 
10
 
4
 
 4E3 cells, and after 24 h the super-
natant was removed and IL-2 production, used as a measure of T
cell activation, was determined. [
 
3
 
H]Thymidine incorporation
upon incubation of the supernatant with the IL-2–dependent
HT-2 cell line was used for detection of IL-2 as described previ-
ously (20).
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Lymph Node and Spleen T Cell Proliferation.
 
Lymph node and
spleen cells were incubated in 96-well flat-bottomed plates at 4 
 
3
 
10
 
5
 
 and 10 
 
3 
 
10
 
5
 
 cells/100 
 
m
 
l per well, respectively, with 100 
 
m
 
l
of stimulator for 3 d. Subsequently, 1 
 
m
 
Ci [
 
3
 
H]thymidine was
added per well, and the culture was continued for an additional
14.5 h. The cells were then harvested on glass fiber filters and in-
corporated [
 
3
 
H]thymidine was counted using the trace 96 pro-
gram and an Inotech 
 
b
 
 counter (Wohlen, Switzerland). The
stimulators were used at the following concentrations: PLP1 and
PLP2 at 15 
 
m
 
g/ml. A control media with no stimulator was in-
cluded for each mouse and used as background.
 
Assays for Restoration of Splenic T Cell Proliferation with Exogenous
Cytokines.
 
Spleen cells from mice that were injected at birth
with Ig–PLP1 and immunized as adults with PLP1 in CFA were
incubated in 96-well flat-bottomed plates at 10 
 
3 
 
10
 
5
 
 cells/100
 
m
 
l per well with 100 
 
m
 
l media containing the stimulator peptide
and the exogenous cytokine (IFN-
 
g
 
 or IL-12) for 3 d. Subse-
quently, 1 
 
m
 
Ci [
 
3
 
H]thymidine was added per well, and the assay
was continued as above.
Cytokine restoration of splenic T cell proliferation was also
carried out in the presence of anti-CD4, anti-I-A
 
s
 
, or isotype-
matched mAb. The rat IgG2b anti-CD4 mAb, GK1.5, was used
at 5 
 
m
 
g/ml and the mouse IgG2b anti–I-A
 
k,r,f,s
 
 mAb, 10-2.16, was
used at 100 
 
m
 
g/ml. Both hybridomas were obtained from the
American Type Culture Collection (Rockville, MD) and anti-
bodies were affinity chromatography purified from culture super-
natant on antiisotypic antibodies coupled to Sepharose.
 
Measurement of Cytokines by ELISA.
 
Spleen cells were incu-
bated in 96-well round-bottomed plates at 10 
 
3 
 
10
 
5
 
 cells/100 
 
m
 
l
per well with 100 
 
m
 
l of stimulator for 24 h. Cytokine production
was measured by ELISA according to PharMingen’s instructions
(San Diego, CA) using 100 
 
m
 
l of culture supernatant. Capture
antibodies were rat anti–mouse IL-2, JES6-1A12; rat anti–mouse
IL-4, 11B11; rat anti–mouse IFN-
 
g
 
, R4-6A2; and rat anti–mouse
IL-10, JES5-2A5. Biotinylated anticytokine antibodies were rat
anti–mouse IL-2, JES6-5H4; rat anti–mouse IL-4, BVD6-24G2;
rat anti–mouse IFN-
 
g
 
, XMG1.2; and rat anti–mouse IL-10,
JES5-16E3. All cytokines and anticytokine antibodies used in
these studies were purchased from PharMingen. The OD
 
405
 
 was
measured on a SpectraMAX 340 counter (Molecular Devices,
Sunnyvale, CA) using SoftMAX PRO version 1.2.0 software.
Graded amounts of recombinant mouse IL-2, IL-4, IFN-
 
g
 
, and
IL-10 were included in all experiments in order to construct stan-
dard curves. The concentration of cytokines in culture superna-
tants was estimated by extrapolation from the linear portion of
the standard curve.
 
Measurement of Cytokines by ELISPOT Assay.
 
ELISPOT as-
say was used to measure cytokines produced by lymph node T
cells during antigen stimulation as previously described (9). HA-
multiscreen plates (Millipore, Bedford, MA) were coated with
100 
 
m
 
l/well 1 M NaHCO
 
3
 
 buffer containing 2 
 
m
 
g/ml capture
antibody. After an overnight incubation at 4
 
8
 
C the plates were
washed three times with sterile PBS and free sites were saturated
with DMEM culture media containing 10% fetal calf serum for 2 h
at 37
 
8
 
C. Subsequently, the blocking media was removed and 5 
 
3
 
10
 
5
 
 lymph node cells/100 
 
m
 
l per well were added along with 100
 
m
 
l of antigen and incubated for 24 h at 37
 
8
 
C in a 7% CO
 
2
 
 hu-
midified chamber. The plates were then washed and 100 
 
m
 
l of
biotinylated anticytokine antibody (1 
 
m
 
g/ml) was added. The
anticytokine antibody pairs used here were those described for
the ELISA technique. After overnight incubation at 4
 
8
 
C the
plates were washed and 100 
 
m
 
l of avidin-peroxidase (2.5 
 
m
 
g/ml)
was added. The plates were then incubated for 1 h at 37
 
8
 
C. Sub-
sequently, spots were visualized by adding 100 
 
m
 
l of substrate (3-
amino-9-ethylcarbazole, from Sigma Chemical Co., St. Louis,
MO) in 50 mM acetate buffer, pH 5.0, and counted under a dis-
secting microscope.
 
Results
 
Neonatal Injection of Ig–PLP1 Circumvents the Use of Adjuvant
and Confers Resistance to EAE Induction.
 
The nucleotide
sequence coding for PLP1 peptide was genetically inserted
into the variable region of an Ig heavy chain gene and the
resulting gene chimera was transfected together with the
gene encoding the parental light chain into the non–Ig-
secreting myeloma B cell line, SP2/0 (20). Selection with
the appropriate drugs allowed for the generation of trans-
fectants producing complete Ig molecules with PLP1 pep-
tide embodied within the heavy chain CDR3 region.
Affinity chromatography–purified Ig–PLP1 was efficiently
presented to PLP1-specific T cell hybridomas (20) and in-
duced in vivo T cell responses in both the lymph nodes and
spleen that were of Th1 type and produced both IL-2 and
IFN-
 
g
 
 (20, 21).
Figure 1. SJL/J mice injected with Ig–PLP1 at birth resist induction of
EAE during adult life. Newborn mice (10 per group) were injected with
100 mg of affinity chromatography–purified Ig–PLP1 (m) or Ig–W (s) in
saline within 24 h of birth and were induced for EAE with free PLP1
peptide at 7 wk of age as described in Materials and Methods. Mice were
scored daily for signs of paralysis for 100 d. A shows the daily mean clini-
cal score of all mice, and B shows the daily mean score of only the surviv-
ing animals. Although all mice in both groups developed signs of paralysis,
40% of the mice that were injected with Ig–W at birth died of severe dis-
ease. Death did not occur in mice injected with Ig–PLP1 at birth. The
mean maximal disease severity was 4.2 6 0.9 in the mice recipient of
Ig–W at birth and 2.7 6 0.5 in the Ig–PLP1 group. 
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To assay for induction of neonatal tolerance, 1-d-old
mice were injected with Ig–PLP1 in saline, and 7 wk later
were challenged with a disease-inducing regimen of free
PLP1 peptide and scored daily for paralysis. As can be seen
in Fig. 1 
 
A
 
, the mice were resistant to induction of paralysis
and developed mild monophasic clinical signs of EAE. The
mean maximal disease severity was 2.7 
 
6
 
 0.5 with 0%
mortality rate. However, mice that were injected with
Ig–W, the parental wild-type Ig not encompassing any PLP
peptide (27), developed severe clinical signs of EAE with a
4.2 
 
6
 
 0.9 mean maximal disease severity accompanied by a
40% mortality. The surviving mice from the group that re-
ceived Ig–W at birth exhibited a relapsing and remitting
disease that persisted to day 100, whereas animals that were
injected with Ig–PLP1 did not display any relapses after re-
covery from the initial mild disease (Fig. 1 
 
B
 
).
 
Mice Injected at Birth with Ig–PLP1 in Saline and Challenged
with PLP1 Peptide in CFA at 7 wk of Age Developed Lymph
Node But Not Splenic Proliferative T Cell Responses. To in-
vestigate the mechanism underlying tolerance induction in
newborn mice, we first determined if Ig–PLP1 is presented
by neonatal APCs in vivo. Mice were injected with Ig–
PLP1 at birth, and 2 d later thymic and splenic cells were
irradiated and assayed for stimulation of the PLP1-specific
T cell hybridoma 4E3 (28) without addition of exogenous
antigen. Fig. 2 shows that both thymic and splenic cells
from mice that were injected with Ig–PLP1 stimulated the
4E3 hybridoma, whereas cells from mice that received
Ig–W instead of Ig–PLP1 did not. These results indicate
that Ig–PLP1 was taken up and processed by neonatal
APCs and that PLP1–I-As complexes were displayed on
the surface of these APCs. Next, we investigated the con-
sequences of such neonatal Ig–PLP1 presentation on the
outcome of a later challenge with PLP1 peptide. Newborn
mice were injected at birth with either Ig–PLP1 or the
control Ig–W, challenged with PLP1 peptide in CFA
when they reached 7 wk of age, and then examined for
proliferative responses in both lymph node and spleen at
day 10 after challenge. The results in Fig. 3 indicate that
those animals, that received Ig–PLP1 at birth developed
proliferative responses to PLP1 peptide in the lymph node
Figure 2. In vivo presentation of Ig–PLP1 by neonatal thymic and
splenic APCs. Newborn mice (three per group) were injected with 100
mg Ig–PLP1 (m) or Ig–W (s) in saline within 24 h of birth, and in vivo
presentation of Ig–PLP1 was allowed for 2 d. The mice were then killed,
and pooled thymic (A) and splenic (B) cells were irradiated and used as
APCs for stimulation of the PLP1-specific T cell hybridoma 4E3 (28). IL-2
production in the supernatant, which was used as a measure of T cell
activation, was determined using the IL-2–dependent HT-2 cell line as
described in Materials and Methods. The indicated cpms represent the
mean 6 SD of triplicates.
Figure 3. Reduced splenic proliferative T cell response in mice in-
jected with Ig–PLP1 at birth. Newborn mice (eight per group) were in-
jected intraperitoneally within 24 h of birth with 100 mg Ig–PLP1 or Ig–W
in saline. When the mice reached 7 wk of age they were immunized
with 100 mg free PLP1 peptide in 200 ml CFA/PBS (vol/vol) subcutane-
ously in the foot pads and at the base of the limbs and tail. 10 d later the
mice were killed, and the (A) lymph node (0.4 3 106 cells/well) and (B)
splenic (1 3 106 cells/well) cells were in vitro stimulated for 4 d with 15
mg/ml of free PLP1 or PLP2, a negative control peptide corresponding to
the encephalitogenic sequence 178–191 of PLP (26). 1 mCi/well of
[3H]thymidine was added during the last 14.5 h of stimulation, and prolif-
eration was measured using an Inotech b-counter and the trace 96 Ino-
tech program. The indicated cpms represent the mean 6 SD of triplicate
wells for individually tested mice. The mean cpm 6 SD of lymph node
proliferative response of all Ig–PLP1 and Ig–W recipient mice was 34,812 6
7,508 and 37,026 6 10,333, respectively. The mean splenic proliferative
response was 3,300 6 3,400 for the Ig–PLP1 recipient group and 14,892 6
4,769 for the Ig–W recipient group.2011 Min et al.
but not the spleen, whereas mice that were injected with
Ig–W developed proliferative responses in both lymphoid
organs. Neither group responded to the negative control
PLP2 peptide, corresponding to amino acid residues 178–
191 of PLP (26). Therefore, exposure to Ig–PLP1 during
the neonatal stage affects the response to a challenge with
PLP1 peptide and leads to lymph node proliferation and
splenic unresponsiveness.
Injection of free PLP1 peptide in saline at birth had no
effect on the outcome of a challenge with PLP1 at 7 wk of
age. Indeed, when newborn mice were injected with PLP1
peptide in saline and challenged at 7 wk of age with PLP1
in CFA, both the lymph node and spleen developed T cell
proliferative responses (Fig. 4). These responses were com-
parable to those obtained in mice that were not subject to
any injection at birth but were immunized with PLP1 pep-
tide in CFA at 7 wk of age. In contrast, mice injected at
birth with free PLP1 peptide emulsified in IFA and chal-
lenged with PLP1 peptide in CFA at the age of 7 wk de-
veloped T cell proliferation in the spleen but were unre-
sponsive in the lymph node (Fig. 4). The slight reduction
in the splenic response in mice recipient of PLP1/IFA at
birth versus those injected with PLP1/saline is not statisti-
cally significant (unpaired Student’s t test analysis, P . 0.1).
The results obtained with PLP1/IFA injection are in good
agreement with data reported for other peptides (9). Con-
sequently, injection of Ig–PLP1 in saline at birth displays an
organ-specific regulation of the T cell that is different from
the regulation induced by injection of free peptide in IFA
or saline (Fig. 4).
Newborn Mice Injected with Ig–PLP1 at Birth Develop a
Lymph Node Deviation and an IFN-g–mediated Splenic Anergy
upon Challenge with PLP1 Peptide in CFA During Adult
Life. Examination of the cytokine production in the
lymph node and spleen of mice injected at birth with Ig–
PLP1 and challenged at 7 wk of age with PLP1 peptide in
CFA revealed yet another unexpected result. As can be
seen in Fig. 5, the lymph node T cells from the Ig–W re-
cipient group produced IL-2 but not IL-4 or IFN-g,
Figure 4. Neonatal injection of free PLP1 peptide in saline or IFA has
a different effect than Ig–PLP1/saline on the proliferative T cell responses
to a challenge with PLP1 in CFA. Three groups of newborn mice (seven
mice per group) were injected at birth intraperitoneally with 100 mg
PLP1 peptide in 100 ml saline (PLP1/Sln), 100 mg PLP1 peptide in 100
ml PBS/IFA (vol/vol) (PLP1/IFA), and 100 mg Ig–PLP1 in 100 ml saline
(Ig–PLP1/Sln), and challenged with 100 mg PLP1 in CFA as in Fig. 3. 10 d
later the mice were killed and lymph node (A) and splenic (B) prolifera-
tive responses were analyzed by [3H]thymidine incorporation as described
in Fig. 3. A control group of mice that was not injected at birth (None)
but immunized as adults with PLP1 in CFA was included for comparison
purposes. The bars represent the mean cpm 6 SD of seven individually
tested mice.
Figure 5. Lymph node T cell deviation in mice recipient of Ig–PLP1 at
birth. Newborn mice (eight per group) were injected intraperitoneally
within 24 h of birth with 100 mg Ig–PLP1 or Ig–W in saline. When the
mice reached 7 wk of age, they were immunized with 100 mg free PLP1
peptide in 200 ml CFA/PBS (vol/vol) subcutaneously in the foot pads
and at the base of the limbs and tail. 10 d later the mice were killed, and
the lymph node cells (0.4 3 106 cells/well) were in vitro stimulated with
free PLP1 or PLP2 (15 mg/ml) for 24 h. The production of IL-2 (A), IL-4
(B), and IFN-g (C) was measured by ELISPOT as described in the Ma-
terials and Methods section using PharMingen anticytokine antibody
pairs. The indicated values (spot forming units, SFU) represent the mean 6
SD of eight individually tested mice.2012 IFN-g–dependent T Cell Anergy and Organ-specific Regulation of Neonatal Tolerance
whereas T cells from the Ig–PLP1 recipient group pro-
duced IL-4 instead of IL-2. This cytokine production
was specific for PLP1 peptide, since PLP2 was unable to
stimulate the cells for cytokine production. In the spleen,
the Ig–W group produced both IL-2 and IFN-g upon
stimulation with PLP1, whereas cells from the Ig–PLP1
group, although nonproliferative, produced IL-2 and
dropped IFN-g to undetectable levels (Fig. 6). In vitro
stimulation with PLP2 peptide had no effect on cytokine
production. IL-4 was undetectable with either stimulation
in both groups of mice (Fig. 6). IL-10 was undetectable in
all groups of mice (data not shown).
Restoration of Splenic T Cell Proliferation and IFN-g Produc-
tion by Exogenous IL-12. Because the splenic cells from
mice that received Ig–PLP1 at birth produced IL-2 but
could not proliferate or secrete IFN-g upon stimulation
with PLP1 peptide, we reasoned that the defect in prolifer-
ation might be related to the deficiency in IFN-g. To ad-
dress this issue, mice that received Ig–PLP1 at birth were
challenged with PLP1 peptide in CFA, and the splenic cells
were in vitro stimulated with PLP1 peptide in the presence
of exogenous IFN-g or IL-12 (an inducer of IFN-g) and
assayed for proliferation. As can be seen in Fig. 7 A, exoge-
nous IFN-g restored proliferation of the spleen cells upon
stimulation with PLP1 peptide. The restoration of prolifer-
ation is antigen specific, since addition of exogenous IFN-g
did not restore proliferation when in vitro stimulation was
carried out with PLP2 peptide. Furthermore, IL-12 was
also able to restore splenic proliferation (Fig. 7 B). IL-12
restoration of proliferation also proved to be antigen spe-
cific and did not develop when in vitro stimulation was
carried out with PLP2 peptide. The restoration of T cell
proliferation by IL-12 was completely inhibited when the in
vitro stimulation was carried out in the presence of 5 mg/ml
of the anti-CD4 mAb, GK 1.5, indicating that the prolifer-
ating cells are CD4 T cells (data not shown). In addition,
the anti–I-As mAb, 10-2.16, inhibited IL-12 restoration of
proliferation, indicating the requirement for peptide pre-
sentation (data not shown).
Although IFN-g–restored splenic T cell proliferation did
not induce IL-4 production, the production of IL-2 was
slightly reduced in comparison to stimulation without cyto-
kine addition (Table 1, IFN-g). In addition, exogenous
IL-12, which restored proliferation but slightly reduced the
Figure 6. Production of IL-2 but not IFN-g by nonproliferative
splenic T cells from mice injected with Ig–PLP1 on the day of birth.
Splenic cells (106 cells/well) from the mice described in Fig. 5 were in
vitro stimulated with free PLP1 or PLP2 (15 mg/ml) for 24 h, and the
production of IL-2 (A), IL-4 (B), and IFN-g (C) in the supernatant was
measured by ELISA using anticytokine antibody pairs from PharMingen
according to the manufacturer’s instructions. The indicated amounts of
cytokine represent the mean 6 SD of eight individually tested mice.
Figure 7. Cytokine-mediated restoration of splenic T cell proliferation
in mice injected with Ig–PLP1 at birth. A group of five newborn mice
was injected intraperitoneally with 100 mg of Ig–PLP1 and immunized
with 100 mg PLP1 peptide in CFA at 7 wk of age, as in Fig. 3. 10 d later,
the splenic cells (106 cells/well) were in vitro stimulated with free PLP1
peptide (15 mg/ml) in the presence of 100 U/ml IFN-g (A) or 10 U/ml
IL-12 (B), and [3H]thymidine incorporation was measured as in Fig. 3.
Cells from each mouse were stimulated with PLP1 peptide without addi-
tion of exogenous cytokines (dotted bars), with PLP1 peptide in the pres-
ence of cytokine (hatched bars), or with PLP2 peptide in the presence of
cytokine (black bars). The indicated cpms for each mouse represent the
mean 6 SD of triplicate wells.2013 Min et al.
amount of IL-2, restored production of IFN-g by the splenic
T cells (Table 1, IL-12). Restoration of IFN-g production
was antigen specific because it required stimulation with
PLP1 and did not occur when PLP2 was used for stimulation.
Restoration of Disease Severity in Ig–PLP1-tolerized Mice by
Administration of Anti–IL-4 Antibody or rIL-12. To evalu-
ate the contribution of lymph node IL-4 and splenic anergy
to the resistance against disease induction, mice, neonatally
tolerized with Ig–PLP1, were subjected to EAE induction
while exposed to anti-IL-4 mAb or rIL-12. As can be seen
in Fig. 8, administration of 11B11 rat anti–mouse IL-4
mAb restored the severity of EAE to a level comparable to
that obtained in the susceptible mice neonatally injected
with Ig–W. The control group injected with rat IgG in-
stead of 11B11 mAb, like the Ig–PLP1 neonatally tolerized
mice that were not given anti–IL-4 during disease induc-
tion, did not restore paralysis. The mice treated with anti–
IL-4 mAb had a 4.0 6 0.9 mean maximal disease severity, a
score comparable to the 4.2 6 0.9 obtained with the Ig–W
tolerized mice, whereas those treated with the rat IgG in-
stead of 11B11 mAb had a mean severity of 2.7 6 0.2,
which is comparable to the 2.7 6 0.5 of the mice tolerized
with Ig–PLP1 but not treated with anti–IL-4. The rate of
mortality was 40% in the anti–IL-4 treated mice and 0% in
those treated with the rat IgG. Overall, in vivo neutraliza-
tion of IL-4 restores severe EAE.
Administration of IL-12 also restores disease severity in
Ig–PLP1 neonatally tolerized mice (Fig. 9). Indeed, mice
injected with Ig–PLP1 during the neonatal stage and ex-
posed to rIL-12 during disease induction developed a pat-
tern of paralysis much more severe than mice that did not
receive rIL-12. In fact, the severity followed a profile simi-
lar to that of the susceptible mice recipient of Ig–W during
the neonatal stage. The mean maximal disease severity in
these mice was 3.8 6 0.8 and the rate of mortality was
29%. These values are significantly higher than the 2.7 6
0.5 mean maximal disease severity and 0% death obtained
in mice that were not administered with rIL-12.
Interestingly, the spleen cells from mice tolerized with
Ig–PLP1 at birth and immunized with PLP1 peptide at
adult life re-acquired proliferative capabilities when the an-
imals were given rIL-12 during peptide immunization (Fig.
10). Indeed, the splenic T cell proliferative responses in
these mice were significantly higher than those obtained in
the mice that were not treated with rIL-12. In addition, the
proliferation was optimal as it was only slightly higher than
the proliferation of cells provided rIL-12 in vitro only and
moderately lower than the proliferation of cells exposed to
rIL-12 both in vivo and in vitro (Fig. 10).
Discussion
Ig–PLP1, an Ig molecule expressing the encephalitoge-
nic sequence 139–151 of PLP, injected in saline into new-
born mice was efficiently presented by neonatal thymic and
Table 1. Restoration of IFN-g Production by Stimulation of 
Splenic Cells from Ig–PLP1 Recipient Mice with PLP1 Peptide in the 
Presence of Exogenous IL-12*
Exogenous
cytokine
Stimulator
peptide
Cytokine production
IFN-g IL-2 IL-4
U/ml pg/ml‡
IFN-g
0 PLP1 #16 322 6 80 #16
1 PLP1 ND 244 6 74 20 6 17
10 PLP1 ND 216 6 60 #16
10 PLP2 ND #16 #16
IL-12
0 PLP1 #16 322 6 80 #16
1 PLP1 675 6 198 242 6 60 31 6 24
10 PLP1 654 6 227 231 6 60 30 6 25
10 PLP2 99 6 78 #16 #16
*Six newborn mice were injected with 100 mg Ig–PLP1 in PBS at birth
and challenged with 100 mg PLP1 peptide in CFA at the age of 7 wk. 10 d
later, the mice were killed and the spleen cells (106 cells/well) were in
vitro stimulated with PLP1 or PLP2 peptide (15 mg/ml) in the presence of
the indicated concentration of IFN-g or IL-12. After 24 h of incubation,
cytokine production was measured in the supernatant by ELISA as de-
scribed in Fig. 6.
‡Mean 6 SD of six individually tested mice.
Statistical analysis using unpaired Student’s t test indicated that the slight
reduction in IL-2 production when the cells were stimulated with PLP1
in the presence of cytokines versus stimulation in the absence of cyto-
kines is not significant (P . 0.05 in all groups). It is likely that reacti-
vated proliferative T cells reabsorb some IL-2. ND, not done.
Figure 8. Restoration of EAE in Ig–PLP1 tolerized mice by administra-
tion of anti–IL-4 antibody. Newborn mice were injected intraperitoneally
within 24 h of birth with 100 mg Ig–PLP1 in saline. When they reached
7 wk of age, a group of seven mice was injected intraperitoneally with
1 mg/mouse of affinity purified 11B11 anti–IL-4 antibody in 500 ml of
PBS (u). A second group of five mice was injected with 1 mg/mouse of
rat IgG in 500 ml PBS (e) to serve as control. On the next day all mice
were induced for EAE with PLP1 peptide as described in Fig. 1. 5 d after
disease induction, the mice were given a second injection of 1 mg/mouse
intraperitoneally of 11B11 or rat IgG. The mice were scored daily for signs
of paralysis. For comparison purposes the clinical scores of the mice de-
scribed in Fig. 1 that were tolerized with Ig–PLP1 (m) or Ig–W (s) at birth
and induced for EAE with PLP1 peptide at 7 wk of age were included.2014 IFN-g–dependent T Cell Anergy and Organ-specific Regulation of Neonatal Tolerance
splenic APCs in vivo (Fig. 2). Consequently, the mice
showed resistance to EAE induction later in life (Fig. 1).
Examination of the T cell responses to PLP1 in mice that
received Ig–PLP1 at birth and challenged with PLP1 at 7 wk
of age indicated a strong peptide-specific proliferative re-
sponse in the lymph node but a markedly reduced splenic
proliferation (Fig. 3). Control animals injected at birth with
Ig–W, the parental Ig not encompassing PLP1 peptide, de-
veloped proliferative responses in both lymphoid organs
(Fig. 3). In the lymph node there was a cytokine deviation
from IL-2, in Ig–W recipient mice, to IL-4 in Ig–PLP1 re-
cipient mice (Fig. 5). In the spleen, the control mice in-
jected with Ig–W at birth produced both IL-2 and IFN-g,
whereas Ig–PLP1 recipient mice, despite the absence of T
cell proliferation produced IL-2 but IFN-g was undetect-
able (Fig. 6). The nonproliferative splenic T cells were able
to recover from this status and proliferated when stimulated
with PLP1 peptide in the presence of IFN-g or IL-12 (Fig.
7). The restoration of proliferation by exogenous cytokines
was inhibited by anti-CD4 and anti-MHC class II antibod-
ies indicating that the target cells are CD4-positive T cells
requiring peptide presentation for reacquisition of the pro-
liferative status. In addition, these splenic T cells, once re-
covered, became able to produce IFN-g (Table 1). In vivo,
when the Ig–PLP1 tolerized mice were given anti-IL-4
mAb during disease induction, the severity of EAE was re-
stored (Fig. 8). Similarly administration of rIL-12 during
peptide immunization or disease induction restored both
splenic proliferation (Fig. 10) and disease severity (Fig. 9).
A summary of these results is illustrated in Table 2. The
overall conclusion that could be drawn from these data is
that the placing of a peptide in the context of an Ig for de-
livery to the neonatal immune system circumvents the use
of IFA to confer resistance to disease induction later in life.
Moreover, the results reveal a new mechanism operating
neonatal tolerance. As indicated in Table 2, the lymph
node T cells were deviated and produced IL-4 instead of
IL-2, and the splenic T cells, although nonproliferative,
produced IL-2 and regained the ability to proliferate when
provided IFN-g or IL-12. We wish to define this phenom-
enon as IFN-g–mediated anergy.
T cell deviation has previously been associated with neo-
natal tolerance in allogeneic (6, 7), viral (11), and peptide/
IFA (9) antigen systems. In the Ig–PLP1 model, there is a
unique organ-specific T cell regulation characterized by a
deviation in the lymph node and an unusual IFN-g–medi-
ated anergy in the spleen. In fact, when free PLP1 peptide
was injected in saline at birth, the response to challenge
with PLP1 in CFA was normal (Fig. 4). Moreover, when
free PLP1 peptide was injected into newborn mice in IFA,
a challenge with PLP1 in CFA induced significant prolifer-
ation in the spleen but the lymph node was unresponsive
(Fig. 4). Similar results were reported in an MBP/IFA
model, where the proliferative splenic T cells were devi-
ated and produced Th2-type cytokines (9). The lymph
node IL-4 may play an important role in the resistance to
disease induction. This statement is supported by the obser-
vation that neutralization of IL-4 by the administration of
anti–IL-4 antibody restores the severity of disease. In addi-
tion, an IL-4–mediated bystander effect (29) may have
been responsible for the suppression of epitope spreading
and related relapses (30, 31) in the Ig–PLP1–tolerized mice.
Figure 9. Restoration of EAE in Ig–PLP1-tolerized mice by administra-
tion of rIL-12. Newborn mice (seven per group) were injected intraperi-
toneally within 24 h of birth with 100 mg Ig–PLP1 in saline, and when the
mice reached 7 wk of age they were induced for EAE with PLP1 peptide as
described in Fig. 1. 4 h after disease induction the mice were injected intra-
peritoneally with 500 ng/mouse of rIL-12 (PharMingen). Additional intra-
peritoneal injections of rIL-12 (500 ng/mouse) were carried out on days 2,
4, and 7 after disease induction. These mice (u) were scored daily for signs
of paralysis. For comparison purposes, the clinical scores of the mice de-
scribed in Fig. 1 that were tolerized with Ig–PLP1 (m) or Ig–W (s) at birth
and induced for EAE with PLP1 peptide at 7 wk of age were included.
Figure 10. Restoration of splenic proliferation in Ig–PLP1 tolerized
mice by administration of IL-12. Newborn mice (seven per group) were
injected intraperitoneally within 24 h of birth with 100 mg Ig–PLP1 in sa-
line and when the mice reached 7 wk of age they were immunized sub-
cutaneously with 100 mg PLP1 peptide in CFA as described in Fig. 3. 4 h
after immunization, the mice were injected intraperitoneally with 500
ng/mouse of rIL-12. Additional intraperitoneal injections of rIL-12 (500
ng/mouse) were carried out on days 2, 4, and 7 after immunization. On
day 10 the mice were killed, and the spleen cells (106/well) were stimu-
lated with PLP1 peptide in the presence (cross-hatched bar) or absence (gray
bar) of rIL-12 (10 U/well), and proliferation was measured as described in
Materials and Methods. For comparison purposes, spleen cells from mice
that did not receive rIL-12 in vivo were stimulated with PLP1 peptide in
the presence (striped bar) or absence (white bar) of rIL-12 (10 U/well).
Each bar represents the mean 6 SD of seven individually tested mice.2015 Min et al.
The second striking observation is that the splenic T cells
of mice injected with Ig–PLP1 at birth and challenged with
PLP1 peptide as adults could not proliferate (Fig. 3 B) or
produce IFN-g (Fig. 6 C). However, there was production
of IL-2 (Fig. 6 A). Moreover, these cells regained the abil-
ity to proliferate when supplied with IFN-g or IL-12, a cy-
tokine defined as an inducer of IFN-g (Fig. 7; references
32, 33). This phenomenon may qualify for the term an-
ergy, with the distinction that the T cells produce IL-2 but
are unable to produce IFN-g. Therefore, we propose the
term IFN-g–mediated anergy to differentiate it from stan-
dard T cell anergy (34). The fact that the T cells produce
IFN-g when they regain proliferative capacity upon supply
of IL-12 further justifies the involvement of IFN-g in this
form of unresponsiveness. Moreover, since administration
of rIL-12 was able to restore both in vivo splenic T cell
proliferation and disease severity, it maybe that bystander
reactivation of these cells is responsible for the residual EAE
observed in Ig–PLP1 tolerized mice. Also, the question as
to the factors involved in the initiation and perpetuation of
these altered cellular responses mediating resistance to dis-
ease induction remains unanswered. On a speculative basis,
it could be reasoned that neonatal presentation of Ig–PLP1
involves specific APCs that strongly attach Ig–PLP1 and
coordinately regulate expression of costimulatory mole-
cules and/or cytokine production. Under these circum-
stances, the T cell–APC interactions and the local cytokine
environment could be affected, leading to the generation of
T cells for which differentiation is still susceptible to regu-
lation. During challenge with antigen these cells would be
subject to organ-specific regulation. Alternatively, neonatal
presentation of Ig–PLP1 could be generating T cells defi-
cient in IFN-g production. During antigen challenge those
restimulated in regional lymph nodes would be subject to
the effects of CFA and possibly default to the Th2 pathway,
whereas those restimulated systemically remain dependent
on IFN-g for proliferation and differentiation.
The deficiency in IFN-g and the dependency of splenic
T cell proliferation on such a cytokine constitute another
puzzle in these observations. IL-12, a key cytokine for the
differentiation of T cells into effector Th1 cells (35, 36) re-
stored proliferation and IFN-g production by splenic T
cells (Fig. 7 B and Table 1). It could be possible that the
splenic T cells, although producing the growth factor IL-2,
are defective in the biochemical signals required for differ-
entiation and consequent IFN-g production.
Overall, neonatal injection of antigen, generally thought
of as a strategy for induction of unresponsiveness appears to
function for immunization in this Ig–peptide model as well
as in other systems (4, 5, 9). In addition, since immune de-
viation provides the possibility for bystander T cell down-
regulation (29, 37), the Ig–peptide strategy may evolve as a
means of vaccination without the need for adjuvant against
autoimmune diseases involving multiple antigens.
Table 2. Summary of the Lymph Node and Splenic Responses to PLP1 Peptide in Mice Recipient of Ig–PLP1 or Ig–W at Birth
Injection at birth Proliferation Cytokine production Response status
Splenic response
Ig–W yes IL-2, IFN-g standard
Ig–PLP1 no, but can only IL-2, but unusual IFN-g–
be restored by IFN-g production mediated anergy
exogenous IFN-g can be restored by
or IL-12 in vitro, exogenous IL-12 in vitro
or IL-12 in vivo
Lymph node response
Ig–W yes IL-2 standard
Ig–PLP1 yes IL-4 IL-4–driven T cell
deviation
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